"Carpipramine"

, asenapine, blonanserin, brexpiprazole, cariprazine, carpipramine, clocapramine, clorotepine, clotiapine, clozapine, iloperidone, levosulpiride, lumateperone, lurasidone, melperone, mosapramine, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, reserpine, risperidone, sertindole, sulpiride, sultopride, tiapride, veralipride, ziprasidone, zotepine, pimavanserin, stepholidine

Fenoprofen [Naproxen sodium] Sulbutiamine [Carpipramine HCl] Fentanyl Natamycin Sulindac Chloral hydrate

] Sulbutiamine [Carpipramine HCl] Fentanyl Natamycin Sulindac Chloral hydrate Flucytosine Nefopam HCl

] Sulbutiamine [Carpipramine HCl] Fentanyl Natamycin Sulindac Chloral hydrate Flucytosine Nefopam HCl

Fenoprofen [Naproxen sodium] Sulbutiamine [Carpipramine HCl] Fentanyl Natamycin Sulindac Chloral hydrate

] Sulbutiamine [Carpipramine HCl] Fentanyl Natamycin Sulindac Chloral hydrate Flucytosine Nefopam HCl

] Sulbutiamine [Carpipramine HCl] Fentanyl Natamycin Sulindac Chloral hydrate Flucytosine Nefopam HCl

[Fenofibrate] Oxalate Streptomycin Carbimazole Fenoprofen [Naproxen sodium] Sulbutiamine [Carpipramine HCl [Fenofibrate] Oxalate Streptomycin Carbimazole Fenoprofen [Naproxen sodium] Sulbutiamine [Carpipramine HCl

[Fenofibrate] Oxalate Streptomycin Carbimazole Fenoprofen [Naproxen sodium] Sulbutiamine [Carpipramine HCl [Fenofibrate] Oxalate Streptomycin Carbimazole Fenoprofen [Naproxen sodium] Sulbutiamine [Carpipramine HCl

[Activity profile of carpipramine. Results of an open trial and a double-blind trial versus doxepin]. During an uncontrolled trial 46 depressed patients (39 endogenous depressions, 5 schizoaffective psychoses and 2 paranoic schizophrenics with depressive syndromes) were treated for 43 days on the average with 3 X 100 mg 1-[3-(10,11-dihydro-5H-dibenz[b,f]-azepin-5-yl)-propyl]-4-piperidino -piperidine-4-carboxamide-dihydrochloride-monohydrate (carpipramine) daily. The clinical impression of the improvement and the results of the Hamilton-Scale for depressions (19 patients, 24 items) showed a clear antidepressive effect of carpipramine. During a double-blind trial 14 patients were treated with carpipramine and 16 with doxepine for 30 days. Most patients suffered from endogenous depressions

[Double-blind clinical study of carpipramine/placebo (author's transl)]. A statistically planned double blind cross-over test with the substances 1-[3-(10,11-dihydro-5H-dibenz[b;f]-azepin-5-yl)-propyl]-4-piperidino-piperidine-4-carboxamide dihydrochloride-monohydrate (carpipramine, BAY b 4343 b) and placebo (BAY b 4343 a) was carried out on 30 long-term hospitalized schizophrenic patients . The study was evaluated by means of the kappa2-test and yielded the following results: 1. It could be statistically proved that carpipramine has a positive effect on psycho-pathological disorders in the behaviour of long-term hospitalized schizophrenic patients (kappa2 = 9.224; FG = 1; p greater than 0.05). 2. As regards the favourable influence of carpipramine on "productive" versus "non-productive" form

[Studies on cardio-circulatory effects of carpipramine. Results of a double-blind study (author's transl)]. For eight weeks 30 psychotic patients with a healthy cardiovascular system received 3 X 50 mg 1-[3-(10,11-dihydro=5H-dibenz[b,f]-azepin-5-yl]-propyl]-4-piperidiono-piperdine-4-carboxamide dihydrochloride-monohydrate (carpipramine) per day with a placebo phase of three weeks either previous and intraventricular conduction and its repolarisation in form of a lengthening were observed; only the WPW-syndrome noticed with one patient might be related to the medication since it occurred at the end of the three weeks during which carpipramine had been administered.

A double-blind comparison of pimozide with carpipramine in schizophrenic patients.